Louise Catherine Ivers, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cholera | 43 | 2023 | 754 | 11.480 |
Why?
|
Cholera Vaccines | 23 | 2023 | 264 | 7.140 |
Why?
|
Haiti | 52 | 2024 | 553 | 4.660 |
Why?
|
Food Supply | 8 | 2024 | 544 | 1.790 |
Why?
|
Disease Outbreaks | 12 | 2023 | 1761 | 1.460 |
Why?
|
Vaccination | 12 | 2023 | 3436 | 1.310 |
Why?
|
Public Health | 8 | 2023 | 2680 | 1.250 |
Why?
|
Sanitation | 4 | 2018 | 83 | 1.200 |
Why?
|
Rural Population | 10 | 2024 | 2322 | 1.170 |
Why?
|
Vibrio cholerae O1 | 3 | 2023 | 243 | 1.170 |
Why?
|
Mass Vaccination | 3 | 2017 | 111 | 1.100 |
Why?
|
Health Facilities | 3 | 2020 | 577 | 1.090 |
Why?
|
Earthquakes | 5 | 2011 | 192 | 1.040 |
Why?
|
Administration, Oral | 14 | 2023 | 4042 | 0.990 |
Why?
|
Malnutrition | 5 | 2024 | 631 | 0.960 |
Why?
|
Relief Work | 3 | 2018 | 131 | 0.950 |
Why?
|
Epidemics | 7 | 2021 | 517 | 0.950 |
Why?
|
Vibrio cholerae | 11 | 2021 | 793 | 0.920 |
Why?
|
Rift Valley Fever | 1 | 2023 | 5 | 0.900 |
Why?
|
Diarrhea | 6 | 2023 | 1319 | 0.890 |
Why?
|
Immunization Programs | 3 | 2020 | 267 | 0.890 |
Why?
|
Antitubercular Agents | 2 | 2024 | 1397 | 0.840 |
Why?
|
Tuberculosis | 5 | 2024 | 2029 | 0.810 |
Why?
|
Contact Tracing | 2 | 2022 | 275 | 0.810 |
Why?
|
Developing Countries | 8 | 2020 | 2906 | 0.750 |
Why?
|
Colonialism | 1 | 2021 | 35 | 0.740 |
Why?
|
Rural Health Services | 3 | 2010 | 393 | 0.740 |
Why?
|
Community Health Services | 3 | 2010 | 659 | 0.720 |
Why?
|
HIV Infections | 18 | 2024 | 17589 | 0.720 |
Why?
|
Surge Capacity | 1 | 2020 | 49 | 0.690 |
Why?
|
Home Childbirth | 1 | 2020 | 55 | 0.680 |
Why?
|
Facility Design and Construction | 1 | 2020 | 85 | 0.670 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3116 | 0.660 |
Why?
|
Pneumonia, Viral | 4 | 2020 | 3239 | 0.650 |
Why?
|
Weapons | 1 | 2018 | 17 | 0.630 |
Why?
|
Nutritional Status | 3 | 2024 | 1627 | 0.630 |
Why?
|
International Cooperation | 5 | 2020 | 1436 | 0.610 |
Why?
|
Communicable Diseases | 3 | 2022 | 873 | 0.610 |
Why?
|
Public-Private Sector Partnerships | 1 | 2019 | 123 | 0.610 |
Why?
|
Starvation | 1 | 2018 | 141 | 0.600 |
Why?
|
Moral Obligations | 1 | 2018 | 91 | 0.590 |
Why?
|
Financial Support | 1 | 2018 | 116 | 0.580 |
Why?
|
Human Rights Abuses | 1 | 2017 | 34 | 0.570 |
Why?
|
United Nations | 2 | 2017 | 151 | 0.560 |
Why?
|
Financial Management | 1 | 2018 | 161 | 0.540 |
Why?
|
Chromatography, Affinity | 1 | 2017 | 525 | 0.540 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2017 | 239 | 0.530 |
Why?
|
Eligibility Determination | 1 | 2020 | 421 | 0.530 |
Why?
|
Poverty | 5 | 2020 | 2720 | 0.520 |
Why?
|
Vaccines, Inactivated | 6 | 2019 | 186 | 0.500 |
Why?
|
Zea mays | 1 | 2016 | 109 | 0.500 |
Why?
|
Pandemics | 6 | 2023 | 8745 | 0.500 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.470 |
Why?
|
Child Abuse, Sexual | 1 | 2017 | 404 | 0.470 |
Why?
|
Hygiene | 3 | 2020 | 95 | 0.460 |
Why?
|
Disasters | 3 | 2011 | 522 | 0.460 |
Why?
|
Water Supply | 2 | 2017 | 204 | 0.460 |
Why?
|
Poverty Areas | 3 | 2016 | 269 | 0.450 |
Why?
|
Delivery of Health Care | 4 | 2020 | 5375 | 0.440 |
Why?
|
Humans | 92 | 2024 | 768887 | 0.440 |
Why?
|
Commerce | 1 | 2018 | 613 | 0.430 |
Why?
|
Food Preferences | 1 | 2016 | 398 | 0.400 |
Why?
|
Physician's Role | 1 | 2018 | 926 | 0.390 |
Why?
|
Seroepidemiologic Studies | 2 | 2023 | 405 | 0.380 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2016 | 1903 | 0.380 |
Why?
|
Tropical Medicine | 1 | 2012 | 52 | 0.380 |
Why?
|
Women's Rights | 1 | 2011 | 66 | 0.380 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2018 | 843 | 0.380 |
Why?
|
Health Services Accessibility | 5 | 2020 | 5520 | 0.370 |
Why?
|
Disease Transmission, Infectious | 1 | 2016 | 560 | 0.370 |
Why?
|
Health Policy | 4 | 2018 | 2700 | 0.370 |
Why?
|
Anti-Retroviral Agents | 2 | 2014 | 1794 | 0.360 |
Why?
|
Self Report | 2 | 2019 | 3773 | 0.330 |
Why?
|
Investments | 1 | 2011 | 149 | 0.330 |
Why?
|
O Antigens | 2 | 2021 | 196 | 0.310 |
Why?
|
Program Evaluation | 1 | 2017 | 2507 | 0.310 |
Why?
|
Vibrio cholerae O139 | 2 | 2021 | 54 | 0.300 |
Why?
|
Premature Birth | 1 | 2020 | 1814 | 0.300 |
Why?
|
Military Personnel | 1 | 2017 | 1264 | 0.300 |
Why?
|
Human Rights | 1 | 2010 | 312 | 0.290 |
Why?
|
Water | 3 | 2018 | 1421 | 0.290 |
Why?
|
Blood Specimen Collection | 1 | 2008 | 238 | 0.280 |
Why?
|
Case-Control Studies | 6 | 2023 | 22294 | 0.280 |
Why?
|
Diet | 2 | 2016 | 8090 | 0.270 |
Why?
|
Internationality | 1 | 2012 | 1008 | 0.260 |
Why?
|
Antibodies, Bacterial | 4 | 2021 | 1478 | 0.250 |
Why?
|
Weather | 1 | 2006 | 234 | 0.240 |
Why?
|
Feces | 3 | 2024 | 1511 | 0.240 |
Why?
|
Adult | 25 | 2024 | 223818 | 0.240 |
Why?
|
Acidosis, Lactic | 1 | 2006 | 145 | 0.230 |
Why?
|
Chlorine | 1 | 2024 | 55 | 0.230 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2010 | 2203 | 0.230 |
Why?
|
Communicable Disease Control | 2 | 2011 | 857 | 0.230 |
Why?
|
Public Sector | 2 | 2019 | 266 | 0.220 |
Why?
|
Health Resources | 2 | 2020 | 951 | 0.220 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2004 | 79 | 0.220 |
Why?
|
Disaster Planning | 1 | 2010 | 559 | 0.220 |
Why?
|
Infant | 11 | 2024 | 36541 | 0.220 |
Why?
|
Employment | 1 | 2010 | 1114 | 0.210 |
Why?
|
Dietary Supplements | 1 | 2016 | 3442 | 0.210 |
Why?
|
Antacids | 1 | 2023 | 94 | 0.210 |
Why?
|
Healthcare Disparities | 2 | 2024 | 3421 | 0.210 |
Why?
|
Yemen | 2 | 2018 | 10 | 0.200 |
Why?
|
Young Adult | 12 | 2021 | 60110 | 0.200 |
Why?
|
Body Mass Index | 3 | 2016 | 13054 | 0.190 |
Why?
|
Female | 30 | 2024 | 397464 | 0.190 |
Why?
|
Male | 29 | 2024 | 365249 | 0.190 |
Why?
|
Anthozoa | 1 | 2021 | 65 | 0.190 |
Why?
|
Cerebrospinal Fluid | 1 | 2004 | 545 | 0.180 |
Why?
|
Communicable Diseases, Emerging | 1 | 2022 | 148 | 0.180 |
Why?
|
Massachusetts | 2 | 2024 | 8888 | 0.180 |
Why?
|
Family Characteristics | 2 | 2018 | 1002 | 0.170 |
Why?
|
Logistic Models | 4 | 2019 | 13317 | 0.170 |
Why?
|
Infant, Newborn | 7 | 2020 | 26394 | 0.170 |
Why?
|
Knowledge | 1 | 2021 | 178 | 0.170 |
Why?
|
Income | 2 | 2020 | 1878 | 0.160 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 4053 | 0.160 |
Why?
|
Child, Preschool | 9 | 2024 | 42684 | 0.160 |
Why?
|
Immunoglobulin A | 3 | 2021 | 992 | 0.150 |
Why?
|
Herpesvirus 4, Human | 1 | 2004 | 1082 | 0.150 |
Why?
|
Uganda | 1 | 2023 | 1354 | 0.150 |
Why?
|
Saudi Arabia | 1 | 2018 | 212 | 0.150 |
Why?
|
Unemployment | 1 | 2020 | 211 | 0.150 |
Why?
|
Treatment Failure | 1 | 2024 | 2663 | 0.150 |
Why?
|
Adolescent | 11 | 2021 | 89247 | 0.150 |
Why?
|
Virus Diseases | 1 | 2004 | 724 | 0.150 |
Why?
|
Sex Factors | 1 | 2011 | 10641 | 0.140 |
Why?
|
World Health Organization | 2 | 2018 | 1327 | 0.140 |
Why?
|
CD4 Lymphocyte Count | 4 | 2015 | 2598 | 0.140 |
Why?
|
Middle Aged | 15 | 2024 | 223740 | 0.140 |
Why?
|
DNA, Viral | 1 | 2004 | 2205 | 0.140 |
Why?
|
Point-of-Care Systems | 1 | 2006 | 1240 | 0.140 |
Why?
|
Telemedicine | 1 | 2014 | 3109 | 0.140 |
Why?
|
Risk Factors | 9 | 2020 | 74971 | 0.130 |
Why?
|
Emergency Medical Services | 1 | 2008 | 1947 | 0.130 |
Why?
|
Pregnancy | 4 | 2020 | 30175 | 0.130 |
Why?
|
Sexually Transmitted Diseases | 1 | 2022 | 668 | 0.130 |
Why?
|
Immunization, Secondary | 1 | 2018 | 373 | 0.130 |
Why?
|
Central Nervous System Neoplasms | 1 | 2004 | 930 | 0.130 |
Why?
|
Bacterial Infections | 1 | 2004 | 1397 | 0.130 |
Why?
|
Immunoglobulin G | 3 | 2023 | 4568 | 0.120 |
Why?
|
Demography | 2 | 2019 | 1643 | 0.120 |
Why?
|
Vaccines | 1 | 2004 | 842 | 0.120 |
Why?
|
Capacity Building | 1 | 2017 | 265 | 0.120 |
Why?
|
Blood Bactericidal Activity | 1 | 2015 | 124 | 0.120 |
Why?
|
Mental Disorders | 2 | 2012 | 6879 | 0.120 |
Why?
|
Endemic Diseases | 1 | 2016 | 190 | 0.120 |
Why?
|
Polymerase Chain Reaction | 1 | 2004 | 6085 | 0.120 |
Why?
|
Interviews as Topic | 2 | 2013 | 2742 | 0.120 |
Why?
|
Bayes Theorem | 1 | 2023 | 2357 | 0.120 |
Why?
|
Child | 9 | 2021 | 80969 | 0.120 |
Why?
|
Molecular Typing | 1 | 2014 | 115 | 0.110 |
Why?
|
Bacterial Typing Techniques | 1 | 2014 | 263 | 0.110 |
Why?
|
Refrigeration | 1 | 2013 | 27 | 0.110 |
Why?
|
Drug Storage | 1 | 2013 | 52 | 0.110 |
Why?
|
Cyclobutanes | 1 | 2014 | 57 | 0.110 |
Why?
|
Microbial Viability | 1 | 2015 | 235 | 0.110 |
Why?
|
Food | 1 | 2018 | 768 | 0.110 |
Why?
|
Prospective Studies | 4 | 2024 | 54950 | 0.110 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14751 | 0.110 |
Why?
|
Academic Medical Centers | 2 | 2021 | 2784 | 0.110 |
Why?
|
Occupational Exposure | 1 | 2004 | 1807 | 0.110 |
Why?
|
Appetite Depressants | 1 | 2014 | 108 | 0.110 |
Why?
|
Language | 1 | 2023 | 1559 | 0.110 |
Why?
|
Urban Health | 1 | 2016 | 535 | 0.110 |
Why?
|
Sex Offenses | 1 | 2017 | 357 | 0.110 |
Why?
|
Delivery, Obstetric | 1 | 2020 | 950 | 0.110 |
Why?
|
Primary Health Care | 1 | 2010 | 4748 | 0.110 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 26384 | 0.100 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 505 | 0.100 |
Why?
|
Anti-HIV Agents | 2 | 2006 | 4576 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2024 | 1886 | 0.100 |
Why?
|
Bangladesh | 3 | 2022 | 741 | 0.100 |
Why?
|
Odds Ratio | 3 | 2021 | 9682 | 0.100 |
Why?
|
Vulnerable Populations | 1 | 2017 | 718 | 0.100 |
Why?
|
Cohort Studies | 4 | 2024 | 41800 | 0.090 |
Why?
|
Motivation | 1 | 2021 | 2030 | 0.090 |
Why?
|
Antibodies, Viral | 1 | 2023 | 3216 | 0.090 |
Why?
|
Cross Infection | 1 | 2020 | 1425 | 0.090 |
Why?
|
Bacteriophages | 1 | 2014 | 382 | 0.090 |
Why?
|
Aged | 8 | 2024 | 171790 | 0.090 |
Why?
|
Medication Adherence | 2 | 2014 | 2192 | 0.090 |
Why?
|
Lesotho | 1 | 2010 | 76 | 0.090 |
Why?
|
Directly Observed Therapy | 1 | 2010 | 139 | 0.080 |
Why?
|
Aged, 80 and over | 4 | 2018 | 59738 | 0.080 |
Why?
|
Focus Groups | 1 | 2016 | 1461 | 0.080 |
Why?
|
Health Surveys | 1 | 2019 | 4055 | 0.080 |
Why?
|
Diabetic Angiopathies | 1 | 2014 | 806 | 0.080 |
Why?
|
United States | 4 | 2021 | 73180 | 0.080 |
Why?
|
Models, Biological | 2 | 2020 | 9499 | 0.080 |
Why?
|
Obstetric Surgical Procedures | 1 | 2008 | 31 | 0.080 |
Why?
|
Personnel Selection | 1 | 2010 | 201 | 0.070 |
Why?
|
National Health Programs | 1 | 2011 | 442 | 0.070 |
Why?
|
Organizational Objectives | 1 | 2009 | 426 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2024 | 65485 | 0.070 |
Why?
|
Fluid Therapy | 1 | 2011 | 587 | 0.070 |
Why?
|
Financing, Government | 1 | 2010 | 473 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2012 | 1836 | 0.070 |
Why?
|
Siphonaptera | 1 | 2006 | 6 | 0.070 |
Why?
|
Ectoparasitic Infestations | 1 | 2006 | 12 | 0.070 |
Why?
|
Superinfection | 1 | 2006 | 62 | 0.060 |
Why?
|
Incidence | 3 | 2020 | 21545 | 0.060 |
Why?
|
B-Lymphocytes | 1 | 2019 | 4794 | 0.060 |
Why?
|
Social Class | 2 | 2011 | 2009 | 0.060 |
Why?
|
Health Care Costs | 1 | 2018 | 3270 | 0.060 |
Why?
|
Qualitative Research | 1 | 2016 | 3143 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2018 | 39394 | 0.060 |
Why?
|
Water Purification | 1 | 2024 | 61 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 954 | 0.060 |
Why?
|
Politics | 1 | 2010 | 822 | 0.060 |
Why?
|
Health Services Needs and Demand | 1 | 2012 | 1407 | 0.060 |
Why?
|
Netherlands | 1 | 2008 | 2277 | 0.060 |
Why?
|
Biomedical Research | 1 | 2018 | 3463 | 0.050 |
Why?
|
Cooperative Behavior | 1 | 2010 | 1515 | 0.050 |
Why?
|
Genetic Variation | 1 | 2017 | 6610 | 0.050 |
Why?
|
Refugees | 1 | 2010 | 615 | 0.050 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2009 | 1360 | 0.050 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 7860 | 0.050 |
Why?
|
Weight Loss | 1 | 2014 | 2720 | 0.050 |
Why?
|
Data Collection | 1 | 2010 | 3322 | 0.050 |
Why?
|
Vaccines, Combined | 1 | 2021 | 70 | 0.050 |
Why?
|
Nurses | 1 | 2011 | 2501 | 0.050 |
Why?
|
Convalescence | 1 | 2021 | 109 | 0.050 |
Why?
|
Interleukin-8 | 1 | 2024 | 705 | 0.050 |
Why?
|
Breast Feeding | 1 | 2009 | 1364 | 0.050 |
Why?
|
Body Weight | 1 | 2011 | 4628 | 0.050 |
Why?
|
Pregnancy Outcome | 1 | 2011 | 2957 | 0.040 |
Why?
|
Viral Load | 2 | 2010 | 3398 | 0.040 |
Why?
|
Prevalence | 2 | 2016 | 15875 | 0.040 |
Why?
|
Vaccines, Conjugate | 1 | 2021 | 334 | 0.040 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2021 | 340 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 10397 | 0.040 |
Why?
|
Antigens, Viral | 1 | 2022 | 996 | 0.040 |
Why?
|
Blood Pressure | 1 | 2014 | 8541 | 0.040 |
Why?
|
Ventilators, Mechanical | 1 | 2020 | 292 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2017 | 81892 | 0.040 |
Why?
|
Travel | 1 | 2004 | 805 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2008 | 5323 | 0.040 |
Why?
|
Gene Transfer, Horizontal | 1 | 2017 | 148 | 0.030 |
Why?
|
Antibody-Producing Cells | 1 | 2016 | 140 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2021 | 1528 | 0.030 |
Why?
|
Patient Compliance | 1 | 2006 | 2701 | 0.030 |
Why?
|
Rwanda | 1 | 2017 | 673 | 0.030 |
Why?
|
Pilot Projects | 1 | 2008 | 8742 | 0.030 |
Why?
|
Pathology | 1 | 2017 | 270 | 0.030 |
Why?
|
Adhesins, Bacterial | 1 | 2014 | 118 | 0.030 |
Why?
|
Bacterial Load | 1 | 2014 | 154 | 0.030 |
Why?
|
Physicians | 1 | 2011 | 4607 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3518 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2007 | 3233 | 0.030 |
Why?
|
Time Factors | 2 | 2019 | 40266 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7472 | 0.030 |
Why?
|
Plasmids | 1 | 2017 | 2269 | 0.030 |
Why?
|
Point Mutation | 1 | 2017 | 1595 | 0.030 |
Why?
|
Quality of Life | 1 | 2014 | 13510 | 0.020 |
Why?
|
Immunologic Memory | 1 | 2019 | 1378 | 0.020 |
Why?
|
Obesity | 1 | 2014 | 13087 | 0.020 |
Why?
|
Bacterial Proteins | 2 | 2014 | 3839 | 0.020 |
Why?
|
Virulence | 1 | 2014 | 1298 | 0.020 |
Why?
|
Azithromycin | 1 | 2011 | 201 | 0.020 |
Why?
|
Dehydration | 1 | 2011 | 216 | 0.020 |
Why?
|
DNA, Bacterial | 1 | 2014 | 1478 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12252 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2017 | 1894 | 0.020 |
Why?
|
Animals, Newborn | 1 | 2014 | 2695 | 0.020 |
Why?
|
Biological Evolution | 1 | 2014 | 1078 | 0.020 |
Why?
|
Rabbits | 1 | 2014 | 4774 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2014 | 15662 | 0.020 |
Why?
|
Vomiting | 1 | 2011 | 655 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2004 | 15471 | 0.020 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 1119 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2011 | 2231 | 0.020 |
Why?
|
Animals | 4 | 2021 | 169408 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 2931 | 0.010 |
Why?
|
Diffusion of Innovation | 1 | 2009 | 732 | 0.010 |
Why?
|
Rural Health | 1 | 2006 | 300 | 0.010 |
Why?
|
Arthritis, Rheumatoid | 1 | 1999 | 3780 | 0.010 |
Why?
|
Overweight | 1 | 2014 | 2445 | 0.010 |
Why?
|
Risk Assessment | 1 | 2004 | 24330 | 0.010 |
Why?
|
Early Diagnosis | 1 | 2007 | 1195 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2021 | 18366 | 0.010 |
Why?
|
Genomics | 1 | 2017 | 5928 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10845 | 0.010 |
Why?
|
Mice | 2 | 2021 | 82074 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2014 | 12469 | 0.010 |
Why?
|
Ireland | 1 | 1999 | 170 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 9618 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2007 | 2200 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2014 | 11934 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2014 | 15955 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 13020 | 0.010 |
Why?
|
Transcription Factors | 1 | 2014 | 12174 | 0.010 |
Why?
|
Age Factors | 1 | 2007 | 18454 | 0.010 |
Why?
|
Mutation | 1 | 2014 | 30266 | 0.010 |
Why?
|
Neoplasms | 1 | 2017 | 22390 | 0.000 |
Why?
|